• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Get ready for ZEPBOUND!!!


<



















No one cares. Everyone is fat and we can’t make enough product. No one can. Everyone at Lilly and Novo can just ride the golden goose to retirement. We’re both set.
 




This little piggy went to GLP1 market, this little piggy stayed home, this little piggy went off GLP1 & this little piggy had none.

wegovy, zepbound? Won’t matter, Americans will find a way to stay large as life!!
 








ZepBound is a brilliant name. Zep, as in ter-ZEP, to remind everyone about the generic name and to of course boost sales for the diabetes version as well. Very smart.